C.H. Robinson Worldwide, Inc. (CHRW) Stock Forecasts

A Texas judge affirmed a $604 million judgment against C.H. Robinson (CHRW) for a 2021 fatal accident. The case, Lipe vs. Lupus Superior, raises concerns for the company due to the verdict size and jury findings on control. CHRW had $5.8 billion in Q2 assets, including $154.9 million in cash.

C.H. Robinson (CHRW) is appealing a $604M judgment in the Lipe v. Lupus Superior case, which held it liable for a 2021 accident. The company argues it followed federal safety standards and did not employ the driver. It calls for a national carrier-safety standard, citing potential market impacts on trucking companies, brokers, and supply chains.

BMO Capital reduced its price target for C.H. Robinson (CHRW) to $160 from $190, citing integration risks from its RXO acquisition. The stock trades at $144.91, with 15 analysts raising earnings estimates. BMO sees 15% upside at through-the-cycle earnings. Other analysts have mixed views on the deal.

C.H. Robinson plans to acquire RXO for $5.8B, creating a larger logistics platform. The deal, expected to close in H1 2027, aims to expand carrier access and services for shippers. It may also reduce competition and increase data concentration. C.H. Robinson expects $300M in annual cost synergies within two years.

Deutsche Bank downgraded C.H. Robinson, citing uncertainty around its RXO deal integration. While long-term cost savings of $300 million are noted, higher leverage may cap upside until progress is shown. Investors await proof of integration success and debt reduction.

C.H. Robinson (CHRW) will acquire RXO (RXO) in a $5.8B deal, valuing RXO at $30.25 per share, a 29% premium. The combined entity will have an enterprise value of over $25B. RXO shareholders will receive cash and stock, with the deal expected to close in H1 2027. CHRW projects $300M in annual cost synergies.